{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunocompromised",
    "query": {
      "condition": "Immunocompromised"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 113,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunocompromised&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:38:05.515Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00979251",
      "title": "Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Oseltamivir Phosphate",
          "type": "DRUG"
        },
        {
          "name": "ADS-8902",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adamas Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "1 Year to 65 Years"
      },
      "enrollment_count": 2,
      "start_date": "2009-09",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2014-04-14",
      "last_synced_at": "2026-05-22T05:38:05.515Z",
      "location_count": 16,
      "location_summary": "San Francisco, California • Hollywood, Florida • Miramar, Florida + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00979251"
    },
    {
      "nct_id": "NCT05545319",
      "title": "A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)",
        "Coronavirus Disease 2019 (COVID-19)",
        "Immunocompromised",
        "Hospitalization",
        "Child, Hospitalized"
      ],
      "interventions": [
        {
          "name": "Nirmatrelvir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Placebo for nirmatrelvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-12-13",
      "completion_date": "2024-01-06",
      "has_results": false,
      "last_update_posted_date": "2023-03-01",
      "last_synced_at": "2026-05-22T05:38:05.515Z",
      "location_count": 2,
      "location_summary": "Cooperstown, New York • New York, New York",
      "locations": [
        {
          "city": "Cooperstown",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05545319"
    },
    {
      "nct_id": "NCT06752512",
      "title": "Remote Temperature Monitoring of Patients At Risk for Developing Fever",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fever",
        "Cancer",
        "Remote Patient Monitoring"
      ],
      "interventions": [
        {
          "name": "Remote Patient Monitoring",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "AION Biosystems",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2023-08-09",
      "completion_date": "2025-01",
      "has_results": false,
      "last_update_posted_date": "2024-12-30",
      "last_synced_at": "2026-05-22T05:38:05.515Z",
      "location_count": 1,
      "location_summary": "Schenectady, New York",
      "locations": [
        {
          "city": "Schenectady",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06752512"
    },
    {
      "nct_id": "NCT02038881",
      "title": "Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "IMVAMUNE®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 87,
      "start_date": "2014-04-28",
      "completion_date": "2017-05-10",
      "has_results": true,
      "last_update_posted_date": "2020-04-02",
      "last_synced_at": "2026-05-22T05:38:05.515Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02038881"
    },
    {
      "nct_id": "NCT04712539",
      "title": "Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Baloxavir Marboxil",
          "type": "DRUG"
        },
        {
          "name": "Oseltamivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2021-10-11",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-05-22T05:38:05.515Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04712539"
    },
    {
      "nct_id": "NCT04691622",
      "title": "Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Viral Infection",
        "Hematopoietic Stem Cell Transplantation (HSCT)",
        "Primary Immunodeficiency Disorders (PID)"
      ],
      "interventions": [
        {
          "name": "Norovirus -specific T-cell (NST) therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Children's National Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "3 Months to 80 Years"
      },
      "enrollment_count": 48,
      "start_date": "2022-03-17",
      "completion_date": "2028-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-05-22T05:38:05.515Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04691622"
    },
    {
      "nct_id": "NCT00002132",
      "title": "Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Candidiasis, Esophageal",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Fluconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-05-22T05:38:05.515Z",
      "location_count": 18,
      "location_summary": "Tucson, Arizona • Los Angeles, California • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002132"
    },
    {
      "nct_id": "NCT02687763",
      "title": "Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "RENAL INSUFFICIENCY, CHRONIC",
        "LIVER FAILURE, ACUTE",
        "HEART DISEASE"
      ],
      "interventions": [
        {
          "name": "ProQuad",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "6 Months to 24 Months"
      },
      "enrollment_count": 5,
      "start_date": "2015-12",
      "completion_date": "2016-11-03",
      "has_results": false,
      "last_update_posted_date": "2019-02-12",
      "last_synced_at": "2026-05-22T05:38:05.515Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02687763"
    },
    {
      "nct_id": "NCT01924793",
      "title": "An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parainfluenza"
      ],
      "interventions": [
        {
          "name": "DAS181-F02 Dry Powder in Bulk",
          "type": "DRUG"
        },
        {
          "name": "DAS181-F02 Nebulized Formulation Inhaled Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ansun Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2013-08",
      "completion_date": "2017-05",
      "has_results": false,
      "last_update_posted_date": "2017-07-19",
      "last_synced_at": "2026-05-22T05:38:05.515Z",
      "location_count": 23,
      "location_summary": "Duarte, California • Orange, California • Palo Alto, California + 18 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01924793"
    },
    {
      "nct_id": "NCT00002015",
      "title": "An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cytomegalovirus Retinitis",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roche Global Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "3 Months to 12 Years"
      },
      "enrollment_count": 20,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-05-22T05:38:05.515Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002015"
    }
  ]
}